70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial

Beckendorf, V.; Guérif, S.; Prisé, É. Le; Cosset, Jean‐Marc; Bougnoux, A.; Chauvet, B.; Salem, Naji; Chapet, O.; S, Bourdain; Bachaud, Jean-Marc; Maingon, P.; Hannoun‐Lévi, Jean‐Michel; Malissard, L.; Simon, Jean‐Marc; Pommier, P.; Hay, M.; Dubray, Bernard; Lagrange, Jean‐Léon; Luporsi, É.; Bey, P.

doi:10.1016/j.ijrobp.2010.03.049

Cited by 402 publications

(248 citation statements)

References 42 publications

(45 reference statements)

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…However, whatever the technique and their degree of sophistication, quality assurance plays a major role in the planning and delivery of RT Randomised studies have shown that escalating the dose into the 74-80 Gy range leads to a significant improvement in 5-year biochemical disease-free survival [62][63][64][65]. In men with intermediate-or high-risk PCa there is also evidence to support an OS benefit from a nonrandomised but well conducted propensity matched retrospective analysis covering a total of 42,481 patients [66].…”

Section: Definitive Radiotherapymentioning

confidence: 99%

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

et al. 2017

View full text Add to dashboard Cite

Section: Definitive Radiotherapymentioning

confidence: 99%

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

et al. 2017

View full text Add to dashboard Cite

“…[9] ). Thus, a treatment plan consists of dose distribution information over a 3D matrix of points overlaid onto the individual's anatomy.…”

Section: Introductionmentioning

confidence: 99%

Multi-Atlas-Based Segmentation of Pelvic Structures from CT Scans for Planning in Prostate Cancer Radiotherapy

Acosta

Dowling

Dréan

et al. 2013

Abdomen and Thoracic Imaging

View full text Add to dashboard Cite

In prostate cancer radiotherapy, the accurate identification of the prostate and organs at risk in planning computer tomography (CT) images is an important part of the therapy planning and optimization. Manually contouring these organs can be a time consuming process and subject to intra-and inter-expert variability. Automatic identification of organ boundaries from these images is challenging due to the poor soft tissue contrast. Atlas-based approaches may provide a priori structural information by propagating manual expert delineations to a new individual space; however the inter-individual variability and registration errors may lead to biased results. Multiatlas approaches can partly overcome some of these difficulties by selecting the most similar atlases among a large data base but the definition of similarity measure between the available atlases and the query individual has still to be addressed. The purpose of this chapter is to explain atlas-based segmentation approaches and the evaluation of different atlas-based strategies to simultaneously segment prostate, bladder and rectum from CT images. A comparison between single and multiple atlases is performed. Experiments on atlas ranking, selection strategies and fusion decision rules are carried out to illustrate the presented methodology. Propagation of labels using two registration strategies are applied and the results of the comparison with manual delineations are reported.

show abstract

“…Dose escalation has been adopted in radical radiotherapy of prostate cancer to make full use of its advantage of improved tumour control outcomes [13]- [20]. The current "standard" dose of primary RT for prostate cancer is now between 75 and 80 Gy, which is 10% to 20% higher than what can be safely delivered with conventional RT techniques [14].…”

Section: Discussionmentioning

confidence: 99%

“…Since many patients diagnosed with non-metastatic prostate cancer have life expectancy longer than 10 years, the choice of RT techniques with minimized radiotherapy-related toxicity is crucial for improving quality of life [15] [21]. However, higher doses have raised the concern of increased normal tissue toxicity, such as gastrointestinal (GI) toxicity and genitourinary (GU) toxicity [13] [22].…”

Section: Discussionmentioning

confidence: 99%

Image-Guided Radiotherapy Dose Escalation in Intermediate and High Risk Cancer Prostate Patients and Its Effect on Treatment Toxicity

Barsoum¹,

Nasr²,

Mahmoud³

et al. 2017

JCT

View full text Add to dashboard Cite

Purpose: To study the effect of escalating radiation dose; in intermediate and high risk prostate cancer patients; via online image-guidance on acute toxicities. Patients and Methods: thirty-eight prostate cancer patients were treated by using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) with online image guided correction via kilo voltage cone beam computed tomography (KV-CBCT)/electronic portal imaging device (EPID) of trans-rectal ultrasound (TRUS)-inserted intraprostatic gold fiduciary markers. High-risk patients received a median dose of 80.5 Gy to prostate and 56 Gy to pelvic nodes in 35 fractions over 7 weeks. Intermediate-risk patients received a similar prostate dose over the same overall treatment time. Acute toxicity (bladder, rectal and bowel symptoms) was reported once weekly during the radiation course and up to 3 months from the end of the radiation course. Results: The image guided (IG)-IMRT allows escalating the radiation dose delivered to the prostate through minimizing the margin of setup error to less than 0.5 cm with subsequent sparing of nearby organs at risk. Out of thirty-eight patients, no patient developed >grade 1 acute rectal toxicity, 7.9% of patients experienced grade 3 urinary toxicity and there was no reported small intestinal toxicity. Conclusion: Escalating the radiation dose more than 80 Gy in intermediate and high risk prostate cancer patients was safe and not associated with grade 3 -4 RTOG toxicity when guided by online verification of intra-prostatic fiducial markers.

show abstract

70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized Trial

Cited by 402 publications

References 42 publications

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Multi-Atlas-Based Segmentation of Pelvic Structures from CT Scans for Planning in Prostate Cancer Radiotherapy

Image-Guided Radiotherapy Dose Escalation in Intermediate and High Risk Cancer Prostate Patients and Its Effect on Treatment Toxicity

Contact Info

Product

Resources

About